Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and Type 2 diabetes mellitus.
Donadon
Valter
V
Balbi
Massimiliano
M
Zanette
Giorgio
G
D006528:Carcinoma, Hepatocellular / Q000209:etiology*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D006946:Hyperinsulinism / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000009:adverse effects; D007328:Insulin / Q000009:adverse effects; D007333:Insulin Resistance; D008108:Liver Diseases, Alcoholic / Q000150:complications*; D008113:Liver Neoplasms / Q000209:etiology*; D008297:Male; D008687:Metformin / Q000009:adverse effects; D016017:Odds Ratio; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013453:Sulfonylurea Compounds
D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D008687:Metformin